Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 7/20 | 0.47 |
| ▸ | ASAH1 | Q13510 | 3/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001043 | 0.89 | ASAH1 (0.41) | PTAFRASAH1GBA1KDM6BKDM4C | |
| SCHEMBL2000223 | 0.89 | CA12 (0.44) | ASAH1ALDH1A1 | |
| SCHEMBL1998575 | 0.83 | HPGD (0.40) | ASAH1KDM6BKDM4CHPGDALDH1A1 | |
| SCHEMBL2000744 | 0.76 | GBA1 (0.42) | PTAFRGBA1HPGDTSHRALDH1A1 | |
| SCHEMBL1999870 | 0.76 | KMT2A (0.42) | ASAH1HPGDALDH1A1 | |
| SCHEMBL2001548 | 0.75 | NR1H2 (0.49) | ASAH1HPGDALDH1A1 | |
| SCHEMBL2001616 | 0.74 | CA12 (0.40) | ASAH1ALDH1A1 | |
| SCHEMBL5186782 | 0.72 | KDM4E (0.43) | ASAH1EPHX2HPGDALDH1A1 | |
| SCHEMBL1998696 | 0.72 | EPHX1 (0.41) | ASAH1EPHX2ALDH1A1NAMPT | |
| SCHEMBL1998329 | 0.72 | ALDH1A1 (0.46) | HPGDTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | claimed |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2019-01-31 | — | — | US | disclosed |
| WO-2018222975-A1 | METHODS FOR THE TREATMENT OF CANCER | RGENIX, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| EP-3402477-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | The Rockefeller University (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017123568-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | PTAFR 279/4885ASAH1 1051/4885GBA1 2832/4885 |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | NR1H3, NR1H2, MCL1 | PTAFR 997/4885ASAH1 218/4885GBA1 807/4885 |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | PTAFR 997/4885ASAH1 218/4885GBA1 807/4885 |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | PTAFR 997/4885ASAH1 218/4885GBA1 807/4885 |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | NR1H4, NR1H3, NR1H2 | PTAFR 183/4885ASAH1 468/4885GBA1 2545/4885 |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | PTAFR 279/4885ASAH1 1051/4885GBA1 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.